Supplementary Tables 3 - 6 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer
Neill Patani(Institute of Cancer Research), Mitch Dowsett(Institute of Cancer Research), Roger A’Hern, Robert Wellings(AstraZeneca (Brazil)), Anita K. Dunbier(University of Otago), Zara Ghazoui(AstraZeneca (Sweden)), Jill Walker(AstraZeneca (United Kingdom)), Justin P.O. Lindemann(University Hospital Ostrava), Alan Mackay(Institute of Cancer Research), Lesley‐Ann Martin(Institute of Cancer Research), Irene Kuter(Massachusetts General Hospital), Elizabeth Anderson(Wellcome Sanger Institute), H Anderson, Qiong Gao, Ricardo Ribas(Institute of Cancer Research)
Cited by 0
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k